Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb dose-finding study of estradiol-based combined contraceptive vaginal rings versus NuvaRing
NL-OMON37236Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of estradiol, nomegestrol, etonogestrel and ethinyl estradiol in contraception (7 arms), sponsored by Merck & Co. Primary endpoints: Inhibition of ovulation incidence and Breakthrough bleeding and spotting incidence in cycle 3. Started Dec 2012; status: active, not recruiting.
02
Drugs
estradiolnomegestroletonogestrelethinyl estradiol
03
Conditions
contraception
Beyond the preview
Go deeper on NL-OMON37236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37236.